Marker Therapeutics is engaged in developing novel T-cell therapies targeted at blood cancers and solid tumors. The company's proprietary Multi-Antigen Recognizing (MAR) T cell technology allows for the recognition and targeting of tumor cells without genetic modifications, with a focus on safety and efficacy in various clinical indications.

Marker Therapeutics

Marker Therapeutics, Inc. | 4,075 followers on LinkedIn. Pioneering a Multi-Antigen Approach | We are a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Marker’s unique cell therapy technology is based on the selective expansion of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens (multiTAA) and kill tumor cells expressing those targets. Once infused into patients, this population of multiTAA-specific T cells attacks multiple tumor targets and acts to activate the patient’s immune system to produce broad spectrum anti-tumor activity.

Wilson Wolf CEO focused on solving cell and gene therapy manufacturing challenges

John Wilson

Senior Human Resources Manager at Marker Therapeutics, Inc.

Nina Sisommout, SHRM-CP

Clinical Project Manager at Marker Therapeutics

Molly Gilbert

Immunologist/Cancer Biologist

Laura S Angelo

Marker Therapeutics, Inc.

📢 Today we reported our third quarter 2024 financial results and provided business updates. Follow the link for more information: https://lnkd.in/g-bjC4Jt #multiTAA #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

📢 Today we reported our second quarter 2024 financial results and provided business updates. Follow the link for more information: https://lnkd.in/gDjQfatn #multiTAA #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

NEWS 💥 NEWS 💥 NEWS! Marker Therapeutics was awarded a $2 million grant from the #NIH Small Business Innovation Research ( #SBIR ) program! ✨ The proceeds of this award will support our Phase 1 APOLLO study, investigating the #safety and #efficacy of MT-601 in patients with non-Hodgkin’s lymphoma who have relapsed following anti-CD19 CAR-T cell therapy. For more information: https://lnkd.in/gHPjgKUf #immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech

Today we announced that Dr. Shouse, the Principal Investigators at City of Hope , was invited to present his experience from our clinical study in patients with #lymphoma (APOLLO study) at the 11th Global Summit on Hematologic Malignancies. Marker’s Phase 1 #APOLLO study is investigating MT-601, a #multiTAA -specific T cell product, for the treatment of patients with #lymphoma who have #relapsed or are #ineligible to receive #CAR T cell therapy. Key Highlights: 🌟 Three patients were treated at City of Hope as part of the #APOLLO study. 🌟 First study participant treated with MT-601 had diffuse large B cell lymphoma (DLBCL) and failed 4 prior lines of therapy, including a relapse within 90 days of CAR T cell therapy. This participant achieved a #CompleteResponse 8 weeks after the second infusion of MT-601 and remains in complete response #9 #months after initial treatment with MT-601. 🌟 Another study participant was diagnosed with follicular lymphoma that transformed into DLBCL. This participant failed 12 lines of therapy, including CAR T cells. 8 weeks after treatment with MT-601, the study participant achieved a #CompleteResponse , which is maintained 3 months following initial treatment with MT-601. 🌟 The third study participant treated at City of Hope had DLBCL with cutaneous involvement and was not eligible for CAR T cell therapy. This participant achieved a #PartialResponse 8 weeks after MT-601 treatment with all lesions decreasing in size including one that has completely resolved. 🌟 Treatment was well tolerated among all patients with no significant treatment-related adverse events. For more information: https://lnkd.in/gVgUburj #immunotherapy #CART #multiTAA #ClinicalTrials #CellTherapy #lymphoma #patients #cancer #biotech

Join our CEO Juan Vera and learn more about Marker’s #multiTAA T cell products and clinical studies. 📅 Date: March 26, 2024 ⏰ Time: 10:00 AM, EDT Don’t miss out! Your virtual seat awaits here: https://lnkd.in/dx_JUSBm During the conference, our team will conduct one-on-one meetings with registered investors to discuss clinical developments, recent achievements, and anticipated milestones. For more information: https://lnkd.in/gkC_h5Uf #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

We are thrilled to present at the H.C. Wainwright & Co., LLC 2nd Annual Cell Therapy Virtual Conference on March 26, 2024! Join our CEO Juan Vera and learn more about Marker’s #multiTAA T cell products and clinical programs. 📅 Date: March 26, 2024 🕙 Time: 10:00 AM, EDT 👉 Register here: https://lnkd.in/dSQTZqkm The presentation will be available for replay starting March 26, 2024 on the Company’s IR website under Events & Presentations. During the conference, our team will conduct one-on-one meetings with registered investors to discuss clinical development, recent achievements, and anticipated milestones. For more information: https://lnkd.in/gkC_h5Uf #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech #lymphoma #AML #PancreaticCancer

💥 Breaking News! Today we announced that the United States Adopted Names ( #USAN ) Council and the World Health Organization ( #WHO ) International Nonproprietary Names ( #INN ) expert committee approved “neldaleucel” as the nonproprietary (generic) name for MT-601, our #multiTAA -specific T cell product candidate for the treatment of patients with #lymphoma . Follow the link for more information: https://lnkd.in/gnjjXXvB #immunotherapy #ClinicalTrials #CellTherapy #patients #cancer #biotech

📢 Exciting News! Today we announced clinical program updates! Key Highlights: 🌟 Strategic prioritization of clinical programs with a focus on MT-601 in CAR relapse patients with #lymphoma based on promising non-clinical and clinical data. 🌟 Promising clinical observations and new directions with MT-401 in patients with #MRD (measurable residual disease) in #AcuteMyeloidLeukemia (AML). For more information click here: https://lnkd.in/gKyPUKeN #immunotherapy #multiTAA #ClinicalTrials #CellTherapy #patients #cancer #biotech #PancreaticCancer

Meet us in San Francisco during J.P. Morgan week from January 8-10! We are excited to kick off the new year with #JPM ! ✨ If you are attending #JPM2024 and want to connect with our team, please contact us. #SanFrancisco #multiTAAs #biotech #innovation #cancer #immunotherapy #AML #lymphoma #healthcare

We are honored to be recognized as part of the 2023 FreeMind Elite! 🌟 The FreeMind Elite is a selection of FreeMind Group clients who have excelled in securing non-dilutive funding and developing medical technologies in the life sciences sector over the past year. Thank you FreeMind Group for this recognition and our existing partnership! 🎉🙌 #FreeMindElite #immunotherapy #multiTAA #ClinicalTrials #CellTherapy #lymphoma #AML #patients #cancer #biotech

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

COM:MARKERTHERAPEUTICS

Marker Therapeutics

Last Close

2.97

22/11 21:00

Market Cap

44.42M

Beta: -

Volume Today

11.73K

Avg: -

Filings Not Available